Trials / Completed
CompletedNCT00069251
Bupropion for the Treatment of Methamphetamine Dependence - 1
Bupropion for the Treatment of Methamphetamine Dependence
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (planned)
- Sponsor
- National Institute on Drug Abuse (NIDA) · NIH
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence
Detailed description
A double-blind, placebo-controlled, parallel-group design study in which 100 subjects will be randomly assigned to placebo or bupropion for 12 weeks with follow-up assessments 4 weeks following treatment. Adaptive randomization will be used to balance treatment groups based on gender.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bupropion |
Timeline
- Start date
- 2003-07-01
- Completion
- 2005-06-01
- First posted
- 2003-09-24
- Last updated
- 2017-01-12
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00069251. Inclusion in this directory is not an endorsement.